Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China

Chen, Haojie; Zhou, Jun; Luo, Jia; Wu, Yanyuan; Qian, Yuhang; Shi, Yuntian; Qu, Fajun; Shi, Bowen; Ding, Jie; Cui, Xingang; Yu, Yongjiang

doi:10.3389/fimmu.2022.901176

Cited by 6 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Luminex’s liquid array-based multiple immunoassay was used in aggressive prostate cancer to screen serum cytokines and identify less invasive and easily applicable serum cytokine-derived biomarkers. Serum TRAIL and IL-10 were identified as new biomarkers for prostate cancer detection and risk stratification ( 45 ). In addition, some articles have reported the characterization of soluble molecules in malignant tumors ( 46 ).…”

Section: Discussionmentioning

confidence: 99%

Cytokine concentration in peripheral blood of patients with colorectal cancer

Chen

Gao

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionThe role of tumour secretory cytokines and peripheral circulatory cytokines in tumour progression has received increasing attention; however, the role of tumour-related inflammatory cytokines in colorectal cancer (CRC) remains unclear. In this study, the concentrations of various cytokines in the peripheral blood of healthy controls and patients with CRC at different stages were compared.MethodsPeripheral blood samples from 4 healthy participants and 22 colorectal cancer patients were examined. Luminex beads were used to evaluate concentration levels of 40 inflammatory cytokines in peripheral blood samples.ResultsIn peripheral blood, compared with healthy controls and early stage (I + II) CRC patients, advanced CRC (III + IV) patients had increased concentrations of mononuclear/macrophage chemotactic-related proteins (CCL7, CCL8, CCL15, CCL2, and MIF), M2 polarization-related factors (IL-1β, IL-4), neutrophil chemotactic and N2 polarization-related cytokines (CXCL2, CXCL5, CXCL6, IL-8), dendritic cells (DCs) chemotactic-related proteins (CCL19, CCL20, and CCL21), Natural killer (NK) cell related cytokines (CXCL9, CXCL10), Th2 cell-related cytokines (CCL1, CCL11, CCL26), CXCL12, IL-2, CCL25, and CCL27, and decreased IFN-γ and CX3CL1 concentrations. The differential upregulation of cytokines in peripheral blood was mainly concentrated in CRC patients with distant metastasis and was related to the size of the primary tumour; however, there was no significant correlation between cytokine levels in peripheral blood and the propensity and mechanism of lymph node metastasis.DiscussionDifferent types of immune cells may share the same chemokine receptors and can co-localise in response to the same chemokines and exert synergistic pro-tumour or anti-tumour functions in the tumour microenvironment. Chemokines and cytokines affect tumour metastasis and prognosis and may be potential targets for treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytokine concentration in peripheral blood of patients with colorectal cancer

Chen

Gao

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Another investigation by Faupel-Badger et al revealed a relationship between IL-10 and PCa risk and disease severity [109]. In addition, IL-10 has been identified as a potential new biomarker for PCa in the most recent study of serum multicytokines screening [110]. P13K in the CRPC xenograft increased the expression of IL-10 in the blood, but voluntary wheel running may decrease this expression [111].…”

Section: Il-9 Il-10 and Il-11 And Pcamentioning

confidence: 99%

The role of proinflammatory cytokines and CXC chemokines (CXCL1–CXCL16) in the progression of prostate cancer: insights on their therapeutic management

Ullah,

Jiao,

Shen

2024

Cell Mol Biol Lett

View full text Add to dashboard Cite

Reproductive cancers are malignancies that develop in the reproductive organs. One of the leading cancers affecting the male reproductive system on a global scale is prostate cancer (PCa). The negative consequences of PCa metastases endure and are severe, significantly affecting mortality and life quality for those who are affected. The association between inflammation and PCa has captured interest for a while. Inflammatory cells, cytokines, CXC chemokines, signaling pathways, and other elements make up the tumor microenvironment (TME), which is characterized by inflammation. Inflammatory cytokines and CXC chemokines are especially crucial for PCa development and prognosis. Cytokines (interleukins) and CXC chemokines such as IL-1, IL-6, IL-7, IL-17, TGF-β, TNF-α, CXCL1–CXCL6, and CXCL8–CXCL16 are thought to be responsible for the pleiotropic effects of PCa, which include inflammation, progression, angiogenesis, leukocyte infiltration in advanced PCa, and therapeutic resistance. The inflammatory cytokine and CXC chemokines systems are also promising candidates for PCa suppression and immunotherapy. Therefore, the purpose of this work is to provide insight on how the spectra of inflammatory cytokines and CXC chemokines evolve as PCa develops and spreads. We also discussed recent developments in our awareness of the diverse molecular signaling pathways of these circulating cytokines and CXC chemokines, as well as their associated receptors, which may one day serve as PCa-targeted therapies. Moreover, the current status and potential of theranostic PCa therapies based on cytokines, CXC chemokines, and CXC receptors (CXCRs) are examined.

show abstract

“…Although most (10/24) were based on a quantitative Polymerase Chain Reaction (qPCR) [42,44,[47][48][49][50][51][52][53]64], six used mass-spectrometry technology [54,[56][57][58]60,61], two analyzed the biomarkers using Nanostring [43,65], and one used Nanostring and ELISA together [46]. Digital PCR [45], chemical analysis [59], haemocytometer and fluorescence microscopy analyses [55], nanoscale flow cytometer [62], and Luminex cytokine immunoassays [63] were reported by one study each.…”

Section: Literature Overviewmentioning

confidence: 99%

“…Lastly, Koo and colleagues reported a panel composed of one mRNA, one miRNA, and one long non-coding RNA (lncRNA) (TMPRESS2:ERG, miR-107 and SChLAP1) [53] as potential risk biomarkers. Among these studies, thirteen based their approach on urine samples [43,44,[46][47][48][51][52][53]56,57,61,64,65], five on plasma [42,45,50,59,62], four on serum [54,58,60,63], and only one used whole blood [55] and semen [49]. Although most (10/24) were based on a quantitative Polymerase Chain Reaction (qPCR) [42,44,[47][48][49][50][51][52][53]64], six used mass-spectrometry technology [54,[56][57][58]60,61], two analyzed the biomarkers using Nanostring [43,65], and one used Nanostring and ELISA together [46].…”

Section: Literature Overviewmentioning

confidence: 99%

Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review

Sequeira,

Salta,

Freitas

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) is one of the most frequently occurring malignancies. Although most cases are not life-threatening, approximately 20% endure an unfavorable outcome. PSA-based screening reduced mortality but at the cost of an increased overdiagnosis/overtreatment of low-risk (lrPCa) and favorable intermediate-risk (firPCa) PCa. PCa risk-groups are usually identified based on serum Prostate-Specific Antigen (PSA), the Gleason score, and clinical T stage, which have consistent although variable specificity or subjectivity. Thus, more effective and specific tools for risk assessment are needed, ideally making use of minimally invasive methods such as liquid biopsies. In this systematic review we assessed the clinical potential and analytical performance of liquid biopsy-based biomarkers for pre-treatment risk stratification of PCa patients. Methods: Studies that assessed PCa pre-treatment risk were retrieved from PubMed, Scopus, and MedLine. PCa risk biomarkers were analyzed, and the studies’ quality was assessed using the QUADAS-2 tool. Results: The final analysis comprised 24 full-text articles, in which case-control studies predominated, mostly reporting urine-based biomarkers (54.2%) and biomarker quantification by qPCR (41.7%). Categorization into risk groups was heterogeneous, predominantly making use of the Gleason score. Conclusion: This systematic review unveils the substantial clinical promise of using circulating biomarkers in assessing the risk for prostate cancer patients. However, the standardization of groups, categories, and biomarker validation are mandatory before this technique can be implemented. Circulating biomarkers might represent a viable alternative to currently available tools, obviating the need for tissue biopsies, and allowing for faster and more cost-effective testing, with superior analytical performance, specificity, and reproducibility.

show abstract

Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China

Cited by 6 publications

References 31 publications

Cytokine concentration in peripheral blood of patients with colorectal cancer

Cytokine concentration in peripheral blood of patients with colorectal cancer

The role of proinflammatory cytokines and CXC chemokines (CXCL1–CXCL16) in the progression of prostate cancer: insights on their therapeutic management

Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review

Contact Info

Product

Resources

About